Innovative statistical method helps determine ideal threshold times in restricted mean survival time analyses. The restricted mean survival time (RMST) analysis technique was introduced in health care ...
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase ...
Share on Pinterest Results from a phase 3 clinical trial show promise for a new standard of care for treating people with advanced cervical cancer. AzmanL/Getty Images A phase 3 clinical trial ...
ORLANDO, Fla. — A new analysis of three decades of clinical trial data confirms that Black patients with acute myeloid leukemia (AML) have worse survival outcomes than White patients. However, ...
With Longer-Term Follow-Up of Western Patients, Ivonescimab Plus Chemotherapy Demonstrated Improving Global OS Trend with Nominal p-value of 0.0332 vs. Chemotherapy Alone; North American Patients’ OS ...
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, announced the first reported median overall survival ...
Certain individuals with cancer were significantly more likely to survive if they received a COVID-19 mRNA vaccine, researchers at the University of Texas MD Anderson Cancer Center reported. This ...
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the Phase III HARMONi trial featuring the novel, potential first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback